Article Type
Changed
Tue, 08/28/2018 - 11:08
Display Headline
Product Update: SureSound+ device; LILETTA single-handed inserter

PRECISE PREABLATION MEASUREMENT

The SureSound® + device is new to the NovaSure® system. Hologic, Inc. says that the SureSound + device provides the precise uterine cavity length measurement to allow NovaSure to effectively deliver ablation to alleviate or end heavy menstrual bleeding without hormonal side effects. According to Hologic, their research indicates high patient satisfaction rates and low complication rates.

The SureSound + device is designed to allow a physician to measure cavity length with one click, unlike traditional sounding methods that require multiple calculations, says Hologic. Hologic indicates that the device is inserted through the cervical canal, the Malecot anchor is deployed on the internal os, and the inner probe’s polyethylene tip is extended to the fundus to gauge uterine cavity length. The single-use device also may reduce the risk of contamination, says Hologic.

The manufacturer indicates the NovaSure procedure is appropriate for treating premenopausal women with heavy periods due to benign causes who have finished childbearing.

FOR MORE INFORMATION, VISIT: http://www.novasure.com/hcp/suresound_plus

 

NEW LILETTA INSERTER

Allergan and Medicines360 announce the launch of a new LILETTA® (levonorgestrel-releasing intrauterine system) 52-mg intrauterine device (IUD) single-handed inserter following US Food and Drug Administration approval in January 2016.

The companies indicate that the LILETTA IUD is for use by women wishing to prevent pregnancy for up to 3 years regardless of parity or body mass index, with a cumulative 3-year efficacy rate of 99.45%. Approval of the new LILETTA single-handed inserter was based on the ACCESS IUS study that enrolled 1,751 US women and also led to LILETTA’s approval. Product marketing materials state that, during the ACCESS IUS study, the success rate for insertions with the new inserter was 99.2%. The original inserter requires a 2-handed technique.

According to Allergan and Medicines360, the new inserter includes: an ergonomic design allowing for single-handed insertion that can be used with either hand, a bendable tube to accommodate the anatomy of the patient during insertion, and the ability to reload the device if needed before insertion.

FOR MORE INFORMATION, VISIT: https://www.liletta.com

Article PDF
Issue
OBG Management - 28(10)
Publications
Topics
Page Number
52
Sections
Article PDF
Article PDF

PRECISE PREABLATION MEASUREMENT

The SureSound® + device is new to the NovaSure® system. Hologic, Inc. says that the SureSound + device provides the precise uterine cavity length measurement to allow NovaSure to effectively deliver ablation to alleviate or end heavy menstrual bleeding without hormonal side effects. According to Hologic, their research indicates high patient satisfaction rates and low complication rates.

The SureSound + device is designed to allow a physician to measure cavity length with one click, unlike traditional sounding methods that require multiple calculations, says Hologic. Hologic indicates that the device is inserted through the cervical canal, the Malecot anchor is deployed on the internal os, and the inner probe’s polyethylene tip is extended to the fundus to gauge uterine cavity length. The single-use device also may reduce the risk of contamination, says Hologic.

The manufacturer indicates the NovaSure procedure is appropriate for treating premenopausal women with heavy periods due to benign causes who have finished childbearing.

FOR MORE INFORMATION, VISIT: http://www.novasure.com/hcp/suresound_plus

 

NEW LILETTA INSERTER

Allergan and Medicines360 announce the launch of a new LILETTA® (levonorgestrel-releasing intrauterine system) 52-mg intrauterine device (IUD) single-handed inserter following US Food and Drug Administration approval in January 2016.

The companies indicate that the LILETTA IUD is for use by women wishing to prevent pregnancy for up to 3 years regardless of parity or body mass index, with a cumulative 3-year efficacy rate of 99.45%. Approval of the new LILETTA single-handed inserter was based on the ACCESS IUS study that enrolled 1,751 US women and also led to LILETTA’s approval. Product marketing materials state that, during the ACCESS IUS study, the success rate for insertions with the new inserter was 99.2%. The original inserter requires a 2-handed technique.

According to Allergan and Medicines360, the new inserter includes: an ergonomic design allowing for single-handed insertion that can be used with either hand, a bendable tube to accommodate the anatomy of the patient during insertion, and the ability to reload the device if needed before insertion.

FOR MORE INFORMATION, VISIT: https://www.liletta.com

PRECISE PREABLATION MEASUREMENT

The SureSound® + device is new to the NovaSure® system. Hologic, Inc. says that the SureSound + device provides the precise uterine cavity length measurement to allow NovaSure to effectively deliver ablation to alleviate or end heavy menstrual bleeding without hormonal side effects. According to Hologic, their research indicates high patient satisfaction rates and low complication rates.

The SureSound + device is designed to allow a physician to measure cavity length with one click, unlike traditional sounding methods that require multiple calculations, says Hologic. Hologic indicates that the device is inserted through the cervical canal, the Malecot anchor is deployed on the internal os, and the inner probe’s polyethylene tip is extended to the fundus to gauge uterine cavity length. The single-use device also may reduce the risk of contamination, says Hologic.

The manufacturer indicates the NovaSure procedure is appropriate for treating premenopausal women with heavy periods due to benign causes who have finished childbearing.

FOR MORE INFORMATION, VISIT: http://www.novasure.com/hcp/suresound_plus

 

NEW LILETTA INSERTER

Allergan and Medicines360 announce the launch of a new LILETTA® (levonorgestrel-releasing intrauterine system) 52-mg intrauterine device (IUD) single-handed inserter following US Food and Drug Administration approval in January 2016.

The companies indicate that the LILETTA IUD is for use by women wishing to prevent pregnancy for up to 3 years regardless of parity or body mass index, with a cumulative 3-year efficacy rate of 99.45%. Approval of the new LILETTA single-handed inserter was based on the ACCESS IUS study that enrolled 1,751 US women and also led to LILETTA’s approval. Product marketing materials state that, during the ACCESS IUS study, the success rate for insertions with the new inserter was 99.2%. The original inserter requires a 2-handed technique.

According to Allergan and Medicines360, the new inserter includes: an ergonomic design allowing for single-handed insertion that can be used with either hand, a bendable tube to accommodate the anatomy of the patient during insertion, and the ability to reload the device if needed before insertion.

FOR MORE INFORMATION, VISIT: https://www.liletta.com

Issue
OBG Management - 28(10)
Issue
OBG Management - 28(10)
Page Number
52
Page Number
52
Publications
Publications
Topics
Article Type
Display Headline
Product Update: SureSound+ device; LILETTA single-handed inserter
Display Headline
Product Update: SureSound+ device; LILETTA single-handed inserter
Sections
Disallow All Ads
Article PDF Media